

Baxter International Inc.
Key Product Line Sales
Period Ended June 30, 2006
(unaudited)
(\$ in millions)

	Q2 2006	Q2 2005 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2006	YTD 2005 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$437	\$397	10%	12%	\$811	\$741	9%	13%
Plasma Proteins ²	213	170	25%	27%	405	340	19%	21%
Antibody Therapy	199	93	114%	114%	382	182	110%	112%
BioSurgery ³	79	70	13%	14%	148	136	9%	11%
Transfusion Therapies	126	140	(10%)	(9%)	250	273	(8%)	(7%)
Other ⁴	67	120	(44%)	(43%)	125	220	(43%)	(41%)
Total BioScience	\$1,121	\$990	13%	15%	\$2,121	\$1,892	12%	15%
Medication Delivery								
IV Therapies ⁵	\$323	\$312	4%	4%	\$627	\$608	3%	5%
Drug Delivery	213	226	(6%)	(5%)	408	430	(5%)	(4%)
Infusion Systems	204	245	(17%)	(17%)	399	475	(16%)	(16%)
Anesthesia	258	282	(9%)	(7%)	470	513	(8%)	(7%)
Other ⁶	14	18	(22%)	(28%)	24	35	(31%)	(31%)
Total Medication Delivery	\$1,012	\$1,083	(7%)	(6%)	\$1,928	\$2,061	(6%)	(5%)
Renal								
PD Therapy	\$408	\$390	5%	6%	\$796	\$767	4%	6%
HD Therapy	108	114	(5%)	(4%)	213	240	(11%)	(10%)
Total Renal⁷	\$516	\$504	2%	4%	\$1,009	\$1,007	-%	2%
TOTAL BAXTER	\$2,649	\$2,577	3%	4%	\$5,058	\$4,960	2%	4%

¹ Prior year sales data has been reclassified to reflect the changes that are described in notes 2, 3, 4 and 7 below.

² Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products. Sales of Tisseel, sales of plasma to third parties, and contract manufacturing revenues were previously reported in Plasma Proteins, and are now reported in other product lines, as detailed below.

³ Includes sales of Tisseel and FloSeal/CoSeal, which were previously reported in Plasma Proteins and Other, respectively.

⁴ Principally includes vaccines and sales of plasma to third parties. The sales of plasma to third parties were previously reported in Plasma Proteins. The prior year sales include contract manufacturing revenues.

⁵ Principally includes intravenous solutions and nutritional products.

⁶ Principally includes other hospital-distributed products.

⁷ Sales of pharmaceutical and certain other products, which were previously reported in Other, are now reported in PD Therapy.